Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

Attovia Therapeutics / Equity Capital Markets

<ul><li>Attovia Therapeutics (NASDAQ: ATTO) made an impressive public market debut Wednesday, finishing its first day of trading well above its initial public offering price after strong institutional demand carried into the secondary market. </li><li> The clinical-stage biotechnology company priced its upsized IPO at $17.00 per share, selling 17.0 million shares to raise $289 million, before opening at $21.00, a 23.53% premium to the offering price.</li><li>Shares traded as high as $22.79, never fell below $20.21, and closed at $21.90, representing a 28.82% gain from the IPO price. </li></ul>

Attovia Therapeutics (NASDAQ: ATTO) made an impressive public market debut Wednesday, finishing its first day of trading well above its initial public offering price after strong institutional demand carried into the secondary market.  The clinical-stage biotechnology company priced its upsized IPO at $17.00 per share, selling 17.0 million shares to raise $289 million, before opening at $21.00, a 23.53% premium to the offering price.Shares traded as high as $22.79, never fell below $20.21, and closed at $21.90, representing a 28.82% gain from the IPO price. 

Attovia Therapeutics (ATTO) Delivers Strong IPO Debut

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>Strong debut: Attovia upsized its IPO and priced above the initial range, reflecting robust institutional demand and multiple-times oversubscribed order books.</li>
<li>Orderly trading: Shares opened strongly, traded within a relatively tight range, and closed near session highs, signaling balanced aftermarket demand.</li>
<li>Clinical execution ahead: Future performance will likely depend on pipeline milestones, with investors watching whether recent first-day biotech gains are monetized.</li>
</ul>


Strong debut: Attovia upsized its IPO and priced above the initial range, reflecting robust institutional demand and multiple-times oversubscribed order books.
Orderly trading: Shares opened strongly, traded within a relatively tight range, and closed near session highs, signaling balanced aftermarket demand.
Clinical execution ahead: Future performance will likely depend on pipeline milestones, with investors watching whether recent first-day biotech gains are monetized.


Attovia Therapeutics (ATTO): Healthy Debut as Strong Demand Carries Shares Higher

<ul><li>Attovia Therapeutics (NASDAQ: ATTO) has filed to raise approximately $200 million through an initial public offering of 12.5 million shares priced between $15.00 and $17.00 per share, implying a midpoint offering size of $200 million and a fully diluted market capitalization of approximately $616 million at the midpoint.</li><li>The offering is being led by Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.</li><li>Attovia is a clinical-stage biotechnology company developing next-generation biologics for immune-mediated diseases using its proprietary ATTOBODY platform. </li></ul>

Attovia Therapeutics (NASDAQ: ATTO) has filed to raise approximately $200 million through an initial public offering of 12.5 million shares priced between $15.00 and $17.00 per share, implying a midpoint offering size of $200 million and a fully diluted market capitalization of approximately $616 million at the midpoint.The offering is being led by Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.Attovia is a clinical-stage biotechnology company developing next-generation biologics for immune-mediated diseases using its proprietary ATTOBODY platform. 

Attovia Therapeutics (ATTO) Targets $200 Million IPO to Advance Next-Generation Biologics

<ul><li>Attovia Therapeutics is expected to list on the Nasdaq under the ticker ATTO, offering 12.50 million shares at a price range of $15.00 to $17.00 per share, targeting approximately $200 million in gross proceeds.</li><li>The company is developing next-generation biologic therapies for immune-mediated diseases using its proprietary ATTOBODY™ platform, which is designed to create multispecific biologics capable of targeting multiple disease pathways within a single molecule.</li><li>Its lead candidate, ATTO-1310, has completed Phase 1 dosing and targets IL-31 for inflammatory skin diseases, while additional pipeline programs are advancing toward the clinic.</li></ul>

Attovia Therapeutics is expected to list on the Nasdaq under the ticker ATTO, offering 12.50 million shares at a price range of $15.00 to $17.00 per share, targeting approximately $200 million in gross proceeds.The company is developing next-generation biologic therapies for immune-mediated diseases using its proprietary ATTOBODY™ platform, which is designed to create multispecific biologics capable of targeting multiple disease pathways within a single molecule.Its lead candidate, ATTO-1310, has completed Phase 1 dosing and targets IL-31 for inflammatory skin diseases, while additional pipeline programs are advancing toward the clinic.

<ul>
<li>Innovative biologics platform: Company’s ATTOBODY technology supports a pipeline of next-generation immune disease therapies.</li>
<li>Lead program advances: ATTO-1310 has completed Phase 1 dosing with encouraging early data in chronic pruritic diseases.</li>
<li>Early-Stage opportunity: Strong biotech sentiment supports the IPO, but limited clinical maturity creates execution risk.</li>
</ul>


Innovative biologics platform: Company’s ATTOBODY technology supports a pipeline of next-generation immune disease therapies.
Lead program advances: ATTO-1310 has completed Phase 1 dosing with encouraging early data in chronic pruritic diseases.
Early-Stage opportunity: Strong biotech sentiment supports the IPO, but limited clinical maturity creates execution risk.


Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

United States

Attovia Therapeutics, Inc. is a biotechnology company. The Company focuses on research and development of therapeutic products for the treatment of patients with high unmet need across immune mediated diseases. Attovia Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Attovia Therapeutics (ATTO US)

Attovia Therapeutics (ATTO) Delivers Strong IPO Debut

Shares finish 28.82% above the IPO price after opening at a 23.53% premium, as institutional demand supports a strong first day of trading.

IPO Prophet

Attovia Therapeutics (ATTO): Healthy Debut as Strong Demand Carries Shares Higher

Attovia's successful IPO reflects strong institutional demand, with future performance hinging on pipeline milestones and potential monetization...

IPO Boutique

Attovia Therapeutics (ATTO) Targets $200 Million IPO to Advance Next-Generation Biologics

Attovia Therapeutics (NASDAQ: ATTO) has filed to raise approximately $200 million through an initial public offering of 12.5 million shares priced...

IPO Prophet

IPO Rating: Attovia Therapeutics

Attovia Therapeutics is expected to list on the Nasdaq under the ticker ATTO, offering 12.50 million shares at a price range of $15.00 to $17.00...

IPO Prophet

Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Attovia Therapeutics (ATTO) Delivers Strong IPO Debut

Shares finish 28.82% above the IPO price after opening at a 23.53% premium, as institutional demand supports a strong first day of trading.

IPO Prophet

Attovia Therapeutics (ATTO): Healthy Debut as Strong Demand Carries Shares Higher

​Attovia's successful IPO reflects strong institutional demand, with future performance hinging on pipeline milestones and potential monetization...

IPO Boutique

Attovia Therapeutics (ATTO) Targets $200 Million IPO to Advance Next-Generation Biologics

Attovia Therapeutics (NASDAQ: ATTO) has filed to raise approximately $200 million through an initial public offering of 12.5 million shares priced...

IPO Prophet

IPO Rating: Attovia Therapeutics

Attovia Therapeutics is expected to list on the Nasdaq under the ticker ATTO, offering 12.50 million shares at a price range of $15.00 to $17.00...

IPO Prophet

Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

​Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...

IPO Boutique

Attovia's successful IPO reflects strong institutional demand, with future performance hinging on pipeline milestones and potential monetization...

Company's innovative ATTOBODY technology shows promise for next-gen immune disease therapies, with lead program ATTO-1310 showing encouraging...